Safety and Efficacy of Small Frequent Paracentesis Using an Indwelling CAtheter Compared With Repeated Large Volume Paracentesis in Cirrhotic Patients With REfractory Ascites
Launched by INSTITUTE OF LIVER AND BILIARY SCIENCES, INDIA · May 22, 2020
Trial Information
Current as of April 27, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cirrhotic patients 18-70 yrs with refractory severe ascites with stable renal function (S.creatinine \< 2 mg/dl).
- Exclusion Criteria:
- • CTP \>12, MELD\>25
- • Prior or current Spontaneous Bacterial Peritonitis (SBP)
- • Recurrent or current overt hepatic encephalopathy
- • Serum Creatinine \>2
- • HVOTO (Hepatic Venous Outflow Tract Obstruction)
- • Hepatic or extrahepatic malignancy
- • Recent UGI bleed
- • Sepsis
- • Serum Sodium \< 120
About Institute Of Liver And Biliary Sciences, India
The Institute of Liver and Biliary Sciences (ILBS) in India is a premier research and healthcare institution dedicated to the advancement of knowledge and treatment in liver, biliary, and related diseases. As a clinical trial sponsor, ILBS is committed to conducting innovative and ethically-driven research to improve patient outcomes and enhance therapeutic options in hepatology. The institute fosters collaboration among multidisciplinary teams of clinicians, researchers, and healthcare professionals, ensuring rigorous scientific methodologies and adherence to regulatory standards. Through its focus on translational research, ILBS aims to bridge the gap between laboratory discoveries and clinical applications, ultimately contributing to the global understanding and management of liver diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Delhi, Delhi, India
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials